Mac,
Great reminder about the goal here with ATL1102. Adding years to the longevity of these boys would be an amazing outcome.
ATL1102 does not compete with Sarepta, Pfizer or anyone else’s drug....it compliments them and makes them better by reducing inflammation.
What a master stroke to get Goolsbee onto ANP board, if only we can get him into an executive role.
He is a key link to the DMD landscape in the US.
How does ATL1102 compare with Vamorolone, page-9
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $85.01M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $103.7K | 1.237M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 204084 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 280000 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |